SCHEMBL23943404

SCHEMBL23943404

COc1cccc(-c2cccc(Oc3cccc(CNS(C)(=O)=O)c3)n2)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B14 Q9BPX1 1/20 0.41
CCNT1 O60563 4/20 0.39
CCNE1 P24864 4/20 0.39
CDK2 P24941 4/20 0.39
CDK9 P50750 4/20 0.39
CCNE2 O96020 2/20 0.39
CCNK O75909 1/20 0.39
CDK1 P06493 1/20 0.39
YES1 P07947 1/20 0.39
LYN P07948 1/20 0.39
FGR P09769 1/20 0.39
SRC P12931 1/20 0.39
CCNB1 P14635 1/20 0.39
CCNA2 P20248 1/20 0.39
EPHA1 P21709 1/20 0.39
ABL2 P42684 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
IRAK1 P51617 1/20 0.39
EPHB1 P54762 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30510828 1.00 HSD17B14 (0.41) HSD17B14CCNT1CCNE1CDK2CDK9
SCHEMBL23943417 0.87 HSD17B14 (0.57) HSD17B14SCN9A
SCHEMBL30510867 0.87 HSD17B14 (0.57) HSD17B14SCN9A
SCHEMBL30510796 0.79 CDK9 (0.49) HSD17B14CCNT1CDK9CDK1CCNB1
SCHEMBL23943341 0.79 CDK9 (0.49) HSD17B14CCNT1CDK9CDK1CCNB1
SCHEMBL23943202 0.78 HSD17B14 (0.50) HSD17B14ALDH1A1MEN1KMT2ARAB9A
SCHEMBL30510843 0.76 KIT (0.44) HSD17B14PFKFB3SCN9AAPLNR
SCHEMBL23943419 0.76 KIT (0.44) HSD17B14PFKFB3SCN9AAPLNR
SCHEMBL23943229 0.75 HSD17B14 (0.59) HSD17B14ALDH1A1MEN1KMT2ARAB9A
SCHEMBL25459530 0.72 HSD17B14 (0.44) HSD17B14ALDH1A1LMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-05-18 US disclosed
WO-2021211974-A1 HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150940-A1 HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 HSD17B14 7/4885CCNT1 3624/4885CCNE1 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.